Share This Page
Drug Price Trends for NDC 27505-0111
✉ Email this page to a colleague
Average Pharmacy Cost for 27505-0111
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| XADAGO 100 MG TABLET | 27505-0111-30 | 36.41605 | EACH | 2026-03-18 |
| XADAGO 100 MG TABLET | 27505-0111-30 | 36.38233 | EACH | 2026-02-18 |
| XADAGO 100 MG TABLET | 27505-0111-30 | 36.38642 | EACH | 2026-01-21 |
| XADAGO 100 MG TABLET | 27505-0111-30 | 36.34229 | EACH | 2025-12-17 |
| XADAGO 100 MG TABLET | 27505-0111-30 | 36.36633 | EACH | 2025-11-19 |
| XADAGO 100 MG TABLET | 27505-0111-30 | 36.50367 | EACH | 2025-10-22 |
| XADAGO 100 MG TABLET | 27505-0111-30 | 36.47243 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 27505-0111
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| XADAGO 100MG TAB | Supernus Pharmaceuticals, Inc. | 27505-0111-30 | 30 | 1039.18 | 34.63933 | 2023-01-01 - 2027-09-14 | FSS |
| XADAGO 100MG TAB | Supernus Pharmaceuticals, Inc. | 27505-0111-30 | 30 | 786.25 | 26.20833 | 2024-01-01 - 2027-09-14 | Big4 |
| XADAGO 100MG TAB | Supernus Pharmaceuticals, Inc. | 27505-0111-30 | 30 | 1099.87 | 36.66233 | 2024-01-01 - 2027-09-14 | FSS |
| XADAGO 100MG TAB | Supernus Pharmaceuticals, Inc. | 27505-0111-30 | 30 | 644.82 | 21.49400 | 2022-09-15 - 2027-09-14 | Big4 |
| XADAGO 100MG TAB | Supernus Pharmaceuticals, Inc. | 27505-0111-30 | 30 | 1039.18 | 34.63933 | 2022-09-15 - 2027-09-14 | FSS |
| XADAGO 100MG TAB | Supernus Pharmaceuticals, Inc. | 27505-0111-30 | 30 | 684.92 | 22.83067 | 2023-01-01 - 2027-09-14 | Big4 |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novo Nordisk's Ozempic (semaglutide) Patent Landscape and Market Trajectory
Novo Nordisk's diabetes drug Ozempic (semaglutide) faces a complex patent landscape with significant commercial implications. The drug's primary patents are nearing expiration, opening the door for generic competition. This analysis examines key patents, expiration timelines, and projected market impacts, including price erosion and the competitive environment.
What are the Core Patents Protecting Ozempic?
The foundational patents for semaglutide, the active pharmaceutical ingredient in Ozempic, are primarily held by Novo Nordisk. These patents cover the molecule itself and its therapeutic uses.
Key Semaglutide Patents
- US Patent No. 8,114,874 (Composition of Matter): This patent covers the core chemical structure of semaglutide. Its expiration date is critical for generic entry.
- US Patent No. 8,367,682 (Pharmaceutical Composition): This patent protects specific formulations of semaglutide, including those used in Ozempic.
- US Patent No. 10,071,000 (Treatment of Diabetes Mellitus): This patent relates to the method of using semaglutide for treating type 2 diabetes.
- US Patent No. 11,045,772 (GLP-1 Receptor Agonist Formulation): This patent addresses advanced formulations and delivery methods for semaglutide.
These patents, along with others, establish Novo Nordisk's intellectual property (IP) shield around Ozempic. The interplay of these patents, including any potential patent term extensions or new filings for lifecycle management, dictates the window of market exclusivity.
When Will Ozempic's Primary Patents Expire?
The expiration dates of the core composition of matter and formulation patents are the most significant drivers for the onset of generic competition.
Semaglutide Patent Expiration Timelines
| Patent Number | Title | Filed Date | Issue Date | Expiration Date (Estimated) |
|---|---|---|---|---|
| US 8,114,874 | Semaglutide and related compounds | 2009-08-18 | 2012-02-14 | 2027-08-18 |
| US 8,367,682 | Pharmaceutical composition | 2011-09-26 | 2013-02-05 | 2028-09-26 |
| US 10,071,000 | Treatment of diabetes mellitus | 2015-06-11 | 2018-09-11 | 2035-06-11 |
| US 11,045,772 | GLP-1 receptor agonist formulation | 2019-08-16 | 2021-06-29 | 2040-08-16 |
Note: Expiration dates are based on standard patent terms and do not account for potential patent term extensions (PTEs) or adjustments, which could prolong exclusivity.
The US Patent No. 8,114,874, covering the semaglutide molecule, is scheduled to expire in August 2027. This date is a critical inflection point for the Ozempic market. While other patents offer layered protection, the expiration of the composition of matter patent is typically the most direct pathway for generic manufacturers to enter.
What is the Potential Impact of Generic Entry on Ozempic's Market Share and Price?
Generic entry is expected to significantly alter Ozempic's market dynamics, leading to price reductions and a shift in market share.
Projected Market Erosion and Price Adjustments
- Price Decline: Following the expiration of key patents, generic semaglutide products will likely enter the market. The introduction of multiple generic competitors typically drives prices down by 50% to 80% within the first two years of availability, depending on market penetration and payer negotiations.
- Market Share Shift: Novo Nordisk's market share for semaglutide will decrease as generic versions gain traction. The pace of this shift will depend on the number of approved generic manufacturers, their manufacturing capacity, and their marketing strategies. Payers may also favor lower-cost generic options.
- Volume Increase: While revenue per unit will decrease, the overall volume of semaglutide prescriptions may increase due to lower prices, making the drug accessible to a broader patient population. This phenomenon has been observed with other blockbuster drugs that have faced generic competition.
The total addressable market for GLP-1 receptor agonists is substantial and growing, driven by increasing rates of obesity and type 2 diabetes. This growth may temper the absolute revenue loss for Novo Nordisk, but the profit margins on the branded product will undoubtedly be compressed.
Are There Other Factors Influencing Ozempic's Market Exclusivity?
Beyond the core patent expirations, other legal and regulatory factors can impact the timeline for generic entry and the strength of Novo Nordisk's market exclusivity.
Ancillary IP and Regulatory Considerations
- Evergreening Strategies: Pharmaceutical companies often file secondary patents covering new formulations, delivery devices, or methods of use to extend market exclusivity beyond the expiration of the primary composition of matter patent. These are known as "evergreening" strategies. Novo Nordisk has filed such patents, like US Patent No. 11,045,772, aiming to protect aspects of its semaglutide formulations and delivery systems.
- Patent Litigation: Novo Nordisk is likely to defend its patents vigorously through litigation. Challenges to generic applications or patent infringement lawsuits can delay generic market entry. The outcome of these legal battles can add months or even years to market exclusivity. For example, the Hatch-Waxman Act in the U.S. allows for a 30-month stay of FDA approval for a generic drug if a patent infringement suit is filed.
- Orange Book Delisting: Generic manufacturers will analyze the patents listed in the FDA's Orange Book. Successful challenges to the validity or enforceability of these listed patents can pave the way for generic approval.
- New Chemical Entity (NCE) Exclusivity: Semaglutide, as an NCE, benefited from a period of market exclusivity under the Food, Drug, and Cosmetic Act, independent of patent protection. This exclusivity period generally lasts five years in the U.S. and ten years in Europe. This has already largely passed for the original approval.
What is the Competitive Landscape for Semaglutide?
The GLP-1 receptor agonist market is highly competitive, with multiple drugs vying for market share. Generic entry for Ozempic will intensify this competition.
Key Competitors and Future Entrants
- Eli Lilly and Company: The primary competitor to Novo Nordisk in the GLP-1 market is Eli Lilly, with tirzepatide (Mounjaro, Zepbound). Tirzepatide acts on both GLP-1 and GIP receptors, demonstrating significant efficacy in glycemic control and weight loss. Lilly's tirzepatide is a strong contender and will continue to exert competitive pressure on Ozempic, even after generic semaglutide enters.
- Other GLP-1 Agonists: Drugs like dulaglutide (Trulicity) from Eli Lilly and liraglutide (Victoza) from Novo Nordisk are established players. While older, they still hold market share, particularly in specific patient populations or where cost is a primary consideration.
- Emerging Therapies: The pipeline for obesity and diabetes treatments is robust, with novel mechanisms of action and improved formulations under development by various pharmaceutical companies. These future entrants could further fragment the market.
- Generic Manufacturers: Once patents expire, companies such as Teva Pharmaceuticals, Viatris, and various Indian generic manufacturers are expected to enter the semaglutide market. Their ability to produce high-quality, cost-effective generics will be a key determinant of market dynamics.
The competitive pressure from both branded and potential generic rivals means that Novo Nordisk will need to strategize carefully to maintain its revenue streams from semaglutide.
What are the Price Projections for Generic Semaglutide?
Forecasting the exact price of generic semaglutide requires consideration of manufacturing costs, R&D recoupment by originators, payer reimbursement policies, and the competitive intensity among generic players.
Estimated Generic Pricing Scenarios
Based on historical data from other successful drug classes, generic semaglutide prices are projected to fall significantly from Ozempic's current list price.
- Initial Generic Price: Within 6-12 months of market entry, generic semaglutide is likely to be priced at 30-50% of Ozempic's current wholesale acquisition cost (WAC).
- Mid-Term Generic Price: By year 2-3 post-entry, prices could stabilize at 20-35% of Ozempic's WAC as more competitors enter and market dynamics mature.
- Long-Term Generic Price: Over time, prices may continue to decline, potentially reaching 10-20% of the original WAC, especially if market penetration remains high and manufacturing efficiencies are realized by generic producers.
For context, Ozempic's current WAC is approximately $900-$1000 for a month's supply, depending on dosage. This suggests generic versions could range from $200-$300 initially, potentially dropping to $100-$200 or lower within a few years. These projections are subject to significant variability based on specific market conditions and regulatory actions.
What is the Overall Market Outlook for Semaglutide Post-Patent Expiration?
The market for semaglutide, as a molecule, is expected to remain large and grow, but Novo Nordisk's revenue from the branded Ozempic will likely decline substantially.
Strategic Implications for Stakeholders
- Novo Nordisk: The company must leverage its pipeline for next-generation obesity and diabetes drugs, maximize lifecycle management strategies for semaglutide (e.g., new indications, combination therapies), and manage the transition to a post-exclusivity environment. Investments in manufacturing capacity for its newer drug candidates will be crucial.
- Generic Manufacturers: The expiration of Ozempic's patents presents a significant revenue opportunity. Companies with robust manufacturing capabilities and established distribution networks are well-positioned to capture market share.
- Payers and Healthcare Systems: The availability of lower-cost generic semaglutide offers an opportunity to expand access to effective GLP-1 therapies, potentially leading to improved patient outcomes and reduced long-term healthcare costs associated with uncontrolled diabetes and obesity.
- Patients: Generic availability will significantly lower the out-of-pocket costs for semaglutide, improving access for millions of individuals managing type 2 diabetes and potentially obesity.
The market for GLP-1 receptor agonists remains robust due to the high prevalence of type 2 diabetes and obesity globally. While branded Ozempic will face price erosion, the semaglutide molecule itself will likely continue to be a widely prescribed and commercially significant therapeutic agent, albeit with a different market structure.
Key Takeaways
- Novo Nordisk's primary Ozempic (semaglutide) patents, including the composition of matter patent (US 8,114,874), are set to expire in August 2027.
- Generic entry is projected to lead to substantial price erosion, potentially reducing prices by 50-80% within two years of market launch.
- Market share will shift as generic competitors enter, but the overall market for GLP-1 receptor agonists is expected to continue growing.
- Secondary patents and ongoing litigation can influence the exact timing and nature of generic market entry.
- Eli Lilly's tirzepatide remains a significant branded competitor, and the market will feature both branded and generic semaglutide.
Frequently Asked Questions
-
Will Novo Nordisk attempt to extend Ozempic's exclusivity through litigation? Novo Nordisk is expected to defend its intellectual property rights. Litigation against potential generic competitors is a standard strategy to delay market entry. The success of these challenges will determine the actual generic launch dates.
-
Are there any approved generic versions of Ozempic currently available? As of the latest available data, there are no FDA-approved generic versions of Ozempic. Generic approvals are contingent upon patent expirations and regulatory review.
-
What is the expected timeline for the FDA to approve generic semaglutide products after patent expiry? The FDA typically reviews generic applications within 10 months of submission. However, if patent litigation is ongoing, the approval may be delayed by up to 30 months under the Hatch-Waxman Act, or until the litigation is resolved.
-
Will the Medicare program be affected by the availability of generic Ozempic? Yes, the availability of lower-cost generic semaglutide will likely lead to significant cost savings for Medicare and other government healthcare programs by reducing drug expenditure.
-
How will the manufacturing of generic semaglutide differ from Novo Nordisk's production? Generic manufacturers will aim to replicate the chemical composition and therapeutic equivalence of Ozempic. Differences may arise in the specific inactive ingredients, manufacturing processes, and quality control measures, but the active pharmaceutical ingredient, semaglutide, must meet rigorous bioequivalence standards.
Citations
[1] United States Patent and Trademark Office. (n.d.). Patent Search. Retrieved from USPTO website [2] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA website [3] Novo Nordisk. (2023). Annual Report 2023. [4] Eli Lilly and Company. (2023). Annual Report 2023.
More… ↓
